AbbVie PE Ratio 2010-2025 | ABBV
Current and historical p/e ratio for AbbVie (ABBV) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AbbVie PE ratio as of July 08, 2025 is 18.27.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| AbbVie PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-07-08 |
189.77 |
|
80.75 |
| 2025-03-31 |
207.60 |
$2.35 |
88.34 |
| 2024-12-31 |
174.43 |
$2.40 |
72.68 |
| 2024-09-30 |
192.30 |
$2.88 |
66.77 |
| 2024-06-30 |
165.50 |
$3.00 |
55.17 |
| 2024-03-31 |
174.08 |
$3.37 |
51.66 |
| 2023-12-31 |
146.74 |
$2.73 |
53.75 |
| 2023-09-30 |
139.75 |
$3.65 |
38.29 |
| 2023-06-30 |
124.93 |
$4.86 |
25.71 |
| 2023-03-31 |
146.43 |
$4.23 |
34.62 |
| 2022-12-31 |
147.09 |
$6.61 |
22.25 |
| 2022-09-30 |
120.92 |
$7.49 |
16.14 |
| 2022-06-30 |
136.72 |
$7.06 |
19.36 |
| 2022-03-31 |
143.48 |
$6.97 |
20.59 |
| 2021-12-31 |
118.61 |
$6.45 |
18.39 |
| 2021-09-30 |
93.36 |
$4.20 |
22.23 |
| 2021-06-30 |
96.42 |
$3.71 |
25.99 |
| 2021-03-31 |
91.52 |
$2.83 |
32.34 |
| 2020-12-31 |
89.57 |
$2.86 |
31.32 |
| 2020-09-30 |
72.23 |
$4.73 |
15.27 |
| 2020-06-30 |
79.99 |
$4.70 |
17.02 |
| 2020-03-31 |
61.16 |
$5.65 |
10.83 |
| 2019-12-31 |
70.13 |
$5.28 |
13.28 |
| 2019-09-30 |
59.11 |
$2.17 |
27.24 |
| 2019-06-30 |
55.92 |
$2.72 |
20.56 |
| 2019-03-31 |
61.16 |
$3.49 |
17.52 |
| 2018-12-31 |
69.12 |
$3.58 |
19.31 |
| 2018-09-30 |
70.16 |
$4.84 |
14.50 |
| 2018-06-30 |
68.03 |
$4.04 |
16.84 |
| 2018-03-31 |
68.79 |
$3.97 |
17.33 |
| 2017-12-31 |
69.78 |
$3.29 |
21.21 |
| 2017-09-30 |
63.67 |
$4.11 |
15.49 |
| 2017-06-30 |
51.50 |
$4.07 |
12.65 |
| 2017-03-31 |
45.82 |
$3.86 |
11.87 |
| 2016-12-31 |
43.59 |
$3.63 |
12.01 |
| 2016-09-30 |
43.51 |
$3.70 |
11.76 |
| 2016-06-30 |
42.33 |
$3.47 |
12.20 |
| 2016-03-31 |
38.69 |
$3.32 |
11.65 |
| 2015-12-31 |
39.71 |
$3.12 |
12.73 |
| 2015-09-30 |
36.13 |
$1.69 |
21.38 |
| 2015-06-30 |
44.29 |
$1.26 |
35.15 |
| 2015-03-31 |
38.27 |
$1.11 |
34.48 |
| 2014-12-31 |
42.47 |
$1.09 |
38.96 |
| 2014-09-30 |
37.20 |
$2.30 |
16.18 |
| 2014-06-30 |
36.08 |
$2.59 |
13.93 |
| 2014-03-31 |
32.57 |
$2.57 |
12.67 |
| 2013-12-31 |
33.20 |
$2.56 |
12.97 |
| 2013-09-30 |
27.87 |
$2.84 |
9.81 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$331.430B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
